TY - JOUR
T1 - Midbrain dopaminergic neurons in the mouse that contain calbindin-D(28k) exhibit reduced vulnerability to MPTP-induced neurodegeneration
AU - Liang, Chang Lin
AU - Sinton, Christopher M.
AU - Sonsalla, Patricia K.
AU - German, Dwight C.
N1 - Funding Information:
This research was supported by grants from the NIH (NS-30406), the James Webb Fund of the Dallas Foundation, the Zigenbein Fund, the Carl and Hortense Thomsen Chair in Alzheimer’s Disease Research, and the Betty Marcus Estate. The authors thank Mr. Larry Manzino for technical assistance, and Ms. Judy Burdette for secretarial assistance.
PY - 1996/12
Y1 - 1996/12
N2 - The calcium-binding protein calbindin-D(28k) (CB) is located in midbrain dopaminergic (DA) neurons that are less vulnerable to degeneration in Parkinson's disease and in an animal model of the disorder, the MPTP-treated monkey. The present study sought to determine whether CB-containing DA neurons are also less vulnerable to degeneration in the MPTP-treated mouse. Double-labelling immunocytochemical staining and computer imaging techniques were employed to map and quantify the tyrosine hydroxylase-, CB- and CB-containing tyrosine hydroxylase neurons in portions of nucleus A9 and nucleus A10 (ventral tegmental area and central linear nucleus) following MPTP treatment in the C57BL/6 mouse. A cumulative dose of 140 mg/kg MPTP produced a significantly greater loss of DA neurons that lack CB in both nucleus A9 (71 ± 4%) and the ventral tegmental area (70 ± 4%), compared to the loss of DA neurons that contain CB (44 ± 6% and 25 ± 14%, respectively). In the central linear nucleus there was no loss of CB-containing DA neurons. These data demonstrate that the presence of CB in midbrain DA neurons identifies a population of cells in the mouse that are less vulnerable to MPTP-induced degeneration. The mouse, therefore, can serve as a useful model in which to investigate the putative neuroprotective effects of CB in an animal model of Parkinson's disease.
AB - The calcium-binding protein calbindin-D(28k) (CB) is located in midbrain dopaminergic (DA) neurons that are less vulnerable to degeneration in Parkinson's disease and in an animal model of the disorder, the MPTP-treated monkey. The present study sought to determine whether CB-containing DA neurons are also less vulnerable to degeneration in the MPTP-treated mouse. Double-labelling immunocytochemical staining and computer imaging techniques were employed to map and quantify the tyrosine hydroxylase-, CB- and CB-containing tyrosine hydroxylase neurons in portions of nucleus A9 and nucleus A10 (ventral tegmental area and central linear nucleus) following MPTP treatment in the C57BL/6 mouse. A cumulative dose of 140 mg/kg MPTP produced a significantly greater loss of DA neurons that lack CB in both nucleus A9 (71 ± 4%) and the ventral tegmental area (70 ± 4%), compared to the loss of DA neurons that contain CB (44 ± 6% and 25 ± 14%, respectively). In the central linear nucleus there was no loss of CB-containing DA neurons. These data demonstrate that the presence of CB in midbrain DA neurons identifies a population of cells in the mouse that are less vulnerable to MPTP-induced degeneration. The mouse, therefore, can serve as a useful model in which to investigate the putative neuroprotective effects of CB in an animal model of Parkinson's disease.
KW - Calbindin-D(28k) double-labelling immunocytochemistry
KW - MPTP
KW - Midbrain dopaminegic neurons
KW - Mouse
UR - http://www.scopus.com/inward/record.url?scp=0030513477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030513477&partnerID=8YFLogxK
U2 - 10.1006/neur.1996.0042
DO - 10.1006/neur.1996.0042
M3 - Article
C2 - 9117542
AN - SCOPUS:0030513477
VL - 5
SP - 313
EP - 318
JO - Experimental Neurology
JF - Experimental Neurology
SN - 0014-4886
IS - 4
ER -